New pyrazole derivatives possessing amino/methanesulphonyl pharmacophore with good gastric safety profile: Design, synthesis, cyclooxygenase inhibition, anti-inflammatory activity and histopathological studies
作者:Khaled R.A. Abdellatif、Eman K.A. Abdelall、Phoebe F. Lamie、Madlen B. Labib、El-Shaymaa El-Nahaas、Marwa M. Abdelhakeem
DOI:10.1016/j.bioorg.2019.103540
日期:2020.1
derivatives Va-c, VIa-c, VIIa-f, and VIII possessing amino/methanesulphonyl moiety as COX-2 pharmacophore were designed and synthesized. All compounds were evaluated for both in vitro COX inhibition and in vivo anti-inflammatory activities and all of them were more potent against COX-2 than COX-1 isozyme and showed good in vivo anti-inflammatory activity. Compounds Va, VIa, VIc and VIIa-c showed good COX-2
设计并合成了具有氨基/甲磺酰基部分作为COX-2药效团的新系列吡唑衍生物Va-c,VIa-c,VIIa-f和VIII。评估了所有化合物的体外COX抑制作用和体内抗炎活性,并且它们均比COX-1同工酶对COX-2更有效,并显示出良好的体内抗炎活性。与COX-2选择性药物相比,化合物Va,VIa,VIc和VIIa-c显示出良好的COX-2 SI(246.8-353.8)。塞来昔布(326.7)。而且,相对于塞来昔布(60.6和82.8%),它们分别在3和5小时后显示出良好的抗炎活性,具有水肿抑制作用(51-86和83-96%)。此外,这些有效的衍生物Va,VIa,VIc和VIIa-c的致溃疡性(溃疡指数= 0.7-2.0)显着低于消炎痛(溃疡指数= 21)。3)与非致癌参考药物塞来昔布(溃疡指数= 1.3)相比具有可接受的致溃疡性。所获得的致溃疡性责任数据揭示了这些衍生物的胃安全性,这已被组织